Key insights
- EnerSys is acquiring Ultralife in an all-cash deal valued at $320 million, including net debt. Ultralife shares surged 145% on the news. The acquisition expands EnerSys' presence in defense power applications, particularly for drones and soldier-worn units, and leverages Ultralife's FEOC-compliant manufacturing. EnerSys expects significant cost synergies and earnings accretion. The deal is funded by cash on hand and is subject to regulatory approval and tender offer.
Investing.com -- Shares of Ultralife Corporation (NASDAQ: ULBI) surged 145% in premarket trading Wednesday following an agreement to be acquired by industrial battery maker Enersys (NYSE: ENS) in an all-cash deal valued at approximately $320 million, including net debt. EnerSys shares also traded higher, rising 2.3% as investors welcomed the strategic push deeper into high-growth defense power applications.
Under the terms of the unanimous transaction, EnerSys will commence a tender offer to purchase all outstanding Ultralife common shares for $16.00 each. The offer represents a 166% premium to Ultralife’s closing stock price on October 26, delivering substantial immediate cash value to its equity holders while ending the company's run as an independent public entity upon closing.
The combination significantly broadens EnerSys' footprint across specialized military hardware, notably within rapidly expanding niches such as drones, counter-unmanned systems, munitions, and soldier-worn power units. Ultralife, which generated $191 million in revenue during fiscal 2025, brings specialized manufacturing assets that comply with Foreign Entity of Concern (FEOC) standards, addressing heightened supply chain scrutiny from defense authorities and international allies.
Operationally, EnerSys plans to leverage Ultralife’s purpose-built facilities to scale its proprietary liquid reserve battery technologies across broader, mission-critical installations. The company expects the transaction to generate $15 million to $20 million in annual run-rate cost synergies within the first 18 months, paving the way for adjusted diluted earnings accretion over the same period.
EnerSys intends to fund the transaction entirely through cash on hand, removing any financing contingencies from the takeover path. The deal remains subject to the tender of a majority of Ultralife's outstanding common stock and customary regulatory clearances, with both management teams targeting a final closing in the first quarter of 2027.
Original Article